Copyright © Inderes 2011 - present. All rights reserved.
Log in to your Inderes Free account to see all free content on this page.
Create account

Immunovia

0.17 SEK

+0.59 %

Less than 1K followers

IMMNOV

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

+0.59 %
-12.42 %
-24.85 %
-34.64 %
-62.24 %
-47.19 %
-97.46 %
-99.61 %
-98.40 %

Immunovia operates in the biotechnology industry and focuses on the development of diagnostic tools for the early detection of cancer. The company's research and development is focused on molecular diagnostics and its products are aimed at healthcare institutions and physicians. The business is global with a strong presence in Europe and North America. Immunovia was founded in 2007 and is headquartered in Lund.

Read more
Market cap
114.76M SEK
Turnover
311.18K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
24.2.
2026

Annual report '25

7.5.
2026

Interim report Q1'26

15.5.
2026

General meeting '26

ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Forum discussions
Clark Kent got there first. Why wouldn’t I, as someone in a risk group, rather take CA19-9, which is even more sensitive? Not to mention the burden caused by false positives (well, that doesn’t bother the test seller, of course). For that $750 price, I would rather get a pancreatic...
9/17/2025, 2:54 PM
2
That is precisely the problem with tests of this kind. If a rare disease like pancreatic cancer is screened, the test should be very accurate to avoid unnecessary false positives. Since the layperson does not understand this and may happily buy the test, there is still that small...
9/17/2025, 7:27 AM
by Clark kent
2
Part of the Inova Health system, Inova Schar Cancer adopts Immunovia’s Pancreasure blood test MFN – 15 Sep 25 Immunovia: Inova Schar Cancer Adopts Immunovia’s PancreaSure Test... LUND, Sweden – Immunovia (publ.), the pancreatic cancer diagnostics company, today announced that its...
9/15/2025, 7:48 AM
by Kolothos Apollonia
2
It’s been a difficult target, with interesting fluctuations recently. And they certainly won’t calm down with the things you mentioned. Pharmaceutical companies offer excitement to life. I own some.
9/2/2025, 10:07 AM
by Cezeta
2
In familial cases, the sensitivity is the same 78%, the specificity is a bit better 94%, so the math is still quite unforgiving. If we consider that the prior probability of finding pancreatic cancer at a single point in time around age 50 is 10/100,000, and for someone with a family...
9/17/2025, 2:47 PM
by Clark kent
1
Approximately 1,000 new pancreatic cancer cases are diagnosed daily worldwide. Most of them too late.
9/17/2025, 1:13 PM
by Reissu
1
The test is initially targeted at risk groups. Pancreatic cancer took my father, so I would gladly go for that test even once a year. There are enough people in risk groups in the world, and the company is only worth about 20 million euros so far.
9/17/2025, 9:36 AM
by Reissu
1
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.